AREC - Arecor Therapeutics announces collaboration on oral GLP-1 drug for diabetes and obesity treatment
(NewsDirect)
Arecor Therapeutics PLC (AIM:AREC) CEOSarah Howell joined Proactive's Stephen Gunnion with details of acollaboration with TRX Biosciences to develop an oral GLP-1 productfor treating type 2 diabetes and obesity.
GLP-1s are therapeutic peptides known for improving blood sugarlevels and promoting weight loss. The market for GLP-1 products isexpected to reach $100 billion by 2030. Currently, GLP-1 treatmentoptions are predominantly injectable, which limits patient complianceand adoption. Arecor aims to develop an oral GLP-1 with enhancedbioavailability, making it a once-daily pill. This development couldsignificantly increase access to effective treatments for theseconditions.
Howell told Proactivethat Arecor is well-positioned for this development due to itssuccessful track record with its Arestat technology platform, whichenhances the profiles of existing therapeutics. The collaboration aimsto overcome challenges faced by the only available oral GLP-1, such aslow bioavailability and the need for dosing on an empty stomach, byleveraging Arecor's technology in conjunction with TRXBiosciences' Lipper core technology.
She said the collaboration complements Arecor's existingdiabetes portfolio, which includes two leading insulin products andGluco, a product for severe hypoglycemia in diabetes patients. Thefocus is on reducing the daily burden of disease management andimproving patient outcomes.
TRXBiosciences was chosen for their complementary technology andexpertise in oral peptide delivery. The initial development phase willlast up to 18 months, aiming to demonstrate the feasibility of astable, orally delivered GLP-1 with improvedbioavailability.
Contact Details
Proactive UKLtd
+44 20 7989 0813
Copyright (c) 2024 TheNewswire - All rights reserved.